A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)
- Citation:
- J Thorac Oncol vol 5 (3) 380-384
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 524
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA032291, CA33601, CA77597, CA11789, U10 CA077658, CA77406, CA35113, CA32291, U10 CA086726, CA41287, U10 CA035279, U10 CA045808, CA03927, U10 CA031946, U10 CA033601, U10 CA077597, CA45808, CA35279, U10 CA114558, U10 CA045418, CA86726, U10 CA041287, U10 CA035113, U10 CA031946-28, CA114558-02, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31983, CA31946, U10 CA003927
- Corr. Author:
- Authors:
- Antonius A. Miller Herbert Pang Lydia Hodgson Nithya Ramnath Gregory A. Otterson Michael J. Kelley Robert A. Kratzke Everett E. Vokes
- Networks:
- Study
- CALGB-30602
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Phase II, Dasatinib, Small cell lung cancer